Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.
about
New developments in atherosclerosis: clinical potential of PCSK9 inhibitionProfile of evolocumab and its potential in the treatment of hyperlipidemiaPCSK9 inhibitors in the prevention of cardiovascular diseaseLowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab.Managing the lipid profile of coronary heart disease patients.Berberine and Its Role in Chronic Disease.PCSK9 as a therapeutic target for cardiovascular disease.Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia.Association of alirocumab therapy with inflammatory lesions of the vocal folds: A case report.
P2860
Q26783407-711527F2-DF4A-4DA6-921B-BB1EF9069129Q27004235-DEC63653-9285-42E7-AB74-95FE0AAE7698Q28071452-F5E6C415-0F22-44C1-A6A0-5DEF14717C38Q37688760-9D6CB588-B69D-45D1-A939-D99CB82B1462Q38285812-617BC904-7E90-487A-8683-03150A1176E1Q38596398-568CD66C-8F8F-4B22-B551-0FA7AFD5DF8AQ38748787-933AE61F-DF40-4767-B7F4-574A9EA4D6F0Q38934909-2EB57331-F8B9-49E1-A6C8-DB6DB5322A5AQ38965186-7EF6504B-699A-496D-A8F9-712891B7EC37Q41822823-589AC2B1-FACA-4B8B-82BB-1BF14BCE7687Q47303571-63395C4B-8BD9-4EA4-8F24-7A15522AD40FQ51277639-464F6743-B245-4AE0-BE7F-75113F516264
P2860
Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety and tolerability of inj ...... ew of available clinical data.
@ast
Safety and tolerability of inj ...... ew of available clinical data.
@en
type
label
Safety and tolerability of inj ...... ew of available clinical data.
@ast
Safety and tolerability of inj ...... ew of available clinical data.
@en
prefLabel
Safety and tolerability of inj ...... ew of available clinical data.
@ast
Safety and tolerability of inj ...... ew of available clinical data.
@en
P2860
P1476
Safety and tolerability of inj ...... ew of available clinical data.
@en
P2093
Elisa Tartagni
Sibel Ertek
P2860
P304
P356
10.1517/14740338.2014.932348
P407
P577
2014-06-24T00:00:00Z